Zymeworks Inc. (ZYME)Healthcare | Biotechnology | Middletown, United States | NasdaqGS
25.33 USD
-0.46
(-1.784%) ⇩
(Oct. 12, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:49 a.m. EDT
The investment case here is entirely dependent on the proposed acquisition of Theravance Biopharma, which appears to be the catalyst driving both the massive analyst upgrades and the heavy options positioning. However, the fundamental reality is starkly different from the hype: the company is reporting a 90.6% decline in revenue, burning cash at a rate of roughly $12 million monthly, and trading at a negative earnings multiple with no dividend to cushion the blow. While the stock has rallied significantly over the last few years, the underlying business metrics are deteriorating rapidly. The options market is clearly hedging against a failed deal or a lower valuation, evidenced by the heavy put buying at key resistance levels. Until the acquisition closes and the financials turn positive, this remains a speculative gamble on a takeover rather than a sound investment in the company's standalone operations. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.118147 |
| MSTL | 0.138950 |
| AutoETS | 0.139698 |
| AutoARIMA | 0.143566 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 6.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.536 |
| Excess Kurtosis | -0.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.917 |
| Revenue per Share | 0.497 |
| Market Cap | 1,817,427,456 |
| Forward P/E | 23.97 |
| Beta | 1.17 |
| Website | https://www.zymeworks.com |
As of Oct. 10, 2026, 6:49 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional breakout. There is heavy open interest in out-of-the-money calls (strikes 30 and 35) suggesting a bullish tailwind expectation, but this is heavily offset by massive put volume and open interest at strikes 30 and 35 for later expirations. The market is pricing in a binary event—likely the proposed acquisition—where the downside protection (puts) is just as aggressively bought as the upside speculation (calls). Implied volatility remains elevated, indicating uncertainty about the deal's finalization.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.38946795 |
| Address1 | 108 Patriot Drive |
| Address2 | Suite A |
| All Time High | 59.03 |
| All Time Low | 4.11 |
| Ask | 32.8 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,299,560 |
| Average Daily Volume3 Month | 738,056 |
| Average Volume | 738,056 |
| Average Volume10Days | 1,299,560 |
| Beta | 1.173 |
| Bid | 19.17 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 1.125 |
| City | Middletown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 25.33 |
| Current Ratio | 6.316 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 25.79 |
| Day Low | 25.19 |
| Debt To Equity | 19.917 |
| Display Name | Zymeworks |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -150,652,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.24 |
| Enterprise To Revenue | 41.552 |
| Enterprise Value | 1,542,705,536 |
| Eps Current Year | 0.93908 |
| Eps Forward | 1.0567 |
| Eps Trailing Twelve Months | -2.06 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 26.5591 |
| Fifty Day Average Change | -1.2290993 |
| Fifty Day Average Change Percent | -0.0462779 |
| Fifty Two Week Change Percent | 38.946796 |
| Fifty Two Week High | 31.34 |
| Fifty Two Week High Change | -6.01 |
| Fifty Two Week High Change Percent | -0.19176772 |
| Fifty Two Week Low | 16.003 |
| Fifty Two Week Low Change | 9.327 |
| Fifty Two Week Low Change Percent | 0.58282816 |
| Fifty Two Week Range | 16.003 - 31.34 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,493,386,200,000 |
| Float Shares | 65,815,406 |
| Forward Eps | 1.0567 |
| Forward P E | 23.970852 |
| Free Cashflow | -65,060,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 231 |
| Fullday Change | -0.460001 |
| Fullday Change Percent | -1.7836409 |
| Fullday Price | 25.33 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -2.46661 |
| Gross Profits | -91,578,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01343 |
| Held Percent Institutions | 0.99179 |
| Implied Shares Outstanding | 71,750,000 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-12-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. |
| Long Name | Zymeworks Inc. |
| Market | us_market |
| Market Cap | 1,817,427,456 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_43279463 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -149,992,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,966,504,127 |
| Number Of Analyst Opinions | 14 |
| Open | 25.68 |
| Operating Cashflow | -119,337,000 |
| Operating Margins | -9.18954 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 302 274 8744 |
| Previous Close | 25.79 |
| Price Eps Current Year | 26.973207 |
| Price Hint | 2 |
| Price To Book | 22.515556 |
| Price To Sales Trailing12 Months | 48.951637 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.855 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.460001 |
| Regular Market Change Percent | -1.78364 |
| Regular Market Day High | 25.79 |
| Regular Market Day Low | 25.19 |
| Regular Market Day Range | 25.19 - 25.79 |
| Regular Market Open | 25.68 |
| Regular Market Previous Close | 25.79 |
| Regular Market Price | 25.33 |
| Regular Market Time | 1,791,835,200 |
| Regular Market Volume | 2,340,889 |
| Return On Assets | -0.24145001 |
| Return On Equity | -0.72306997 |
| Revenue Growth | -0.906 |
| Revenue Per Share | 0.497 |
| Sand P52 Week Change | 0.17318833 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 71,200,000 |
| Shares Percent Shares Out | 0.073699996 |
| Shares Short | 5,291,136 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,724,831 |
| Short Name | Zymeworks Inc. |
| Short Percent Of Float | 0.111499995 |
| Short Ratio | 6.62 |
| Source Interval | 15 |
| State | DE |
| Symbol | ZYME |
| Target High Price | 60.0 |
| Target Low Price | 32.0 |
| Target Mean Price | 41.21429 |
| Target Median Price | 38.0 |
| Total Cash | 270,699,008 |
| Total Cash Per Share | 3.815 |
| Total Debt | 16,007,000 |
| Total Revenue | 37,127,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.078026 |
| Two Hundred Day Average Change | 0.2519741 |
| Two Hundred Day Average Change Percent | 0.010047605 |
| Type Disp | Equity |
| Volume | 2,340,889 |
| Website | https://www.zymeworks.com |
| Zip | 19,709 |